ADALIMUMAB BS SUBCUTANEOUS INJECTION 40mg PEN 0.8mL "DAIICHI SANKYO" (アダリムマブBS皮下注40mgペン0.8mL「第一三共」)

البلد: اليابان

اللغة: الإنجليزية

المصدر: すりの適正使用協議会 RAD-AR Council, Japan

العنصر النشط:

Adalimumab (genetical recombination) [adalimumab biosimilar 2]

متاح من:

DAIICHI SANKYO COMPANY, LIMITED

INN (الاسم الدولي):

Adalimumab (genetical recombination) [adalimumab biosimilar 2]

الشكل الصيدلاني:

injection

نشرة المعلومات

Drug Information Sheet("Kusuri-no-Shiori")
Self-injection
Revised: 11/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
ADALIMUMAB BS SUBCUTANEOUS INJECTION
40MG PEN 0.8ML "DAIICHI SANKYO"
ACTIVE INGREDIENT:
Adalimumab (genetical recombination) [adalimumab
biosimilar 2]
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine suppresses function of TNF (tumor necrosis factor) α,
which is one of the
possible primary causative substances in rheumatoid arthritis,
psoriasis, ankylosing
spondylitis, juvenile idiopathic arthritis, Crohn's disease and
ulcerative colitis. TNF is one of
the cytokines existing inside of the body even in a healthy state, and
involved in activities of
immunity and development of inflammation or pain.
It is usually used to treat rheumatoid arthritis (including prevention
of structural joint damage)
and diseases described below with inadequate response to conventional
therapies: active
polyarticular-juvenile idiopathic arthritis; psoriasis vulgaris,
psoriasis arthritis or pustular
psoriasis; ankylosing spondylitis; intestinal Behcet's disease;
non-infectious
intermediate/posterior uveitis or panuveitis; and moderate to severe
ulcerative colitis.
It is also used for inducing clinical remission and maintenance
therapy in patient with
moderately to severely active Crohn's disease.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have or are suspected of having infections such as sepsis.
If you have or have a history of tuberc